Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308555 | 0.92 | LRRK2 (0.33) | ALDH1A1MEN1GAAKMT2ALRRK2 | |
| SCHEMBL2509469 | 0.92 | NPC1 (0.35) | ALDH1A1MEN1GAAKMT2ALRRK2 | |
| SCHEMBL2511802 | 0.89 | LRRK2 (0.39) | ALDH1A1MEN1GAAKMT2ALRRK2 | |
| SCHEMBL2304851 | 0.89 | ALDH1A1 (0.35) | ALDH1A1MEN1GAAKMT2ALRRK2 | |
| SCHEMBL2506176 | 0.88 | SCN9A (0.34) | ALDH1A1MEN1GAAKMT2ALRRK2 | |
| SCHEMBL2309302 | 0.87 | LRRK2 (0.33) | ALDH1A1MEN1GAAKMT2ALRRK2 | |
| SCHEMBL2312393 | 0.87 | SLC16A3 (0.31) | ALDH1A1MEN1GAAKMT2ASCN9A | |
| SCHEMBL2507386 | 0.87 | TNKS (0.32) | ALDH1A1MEN1GAAKMT2ALRRK2 | |
| SCHEMBL2511638 | 0.87 | SCN9A (0.35) | ALDH1A1MEN1GAAKMT2ALRRK2 | |
| SCHEMBL2310416 | 0.85 | MAPK1 (0.38) | ALDH1A1MEN1GAAKMT2ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350077-B1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS LTD (GB) | 2016-01-27 | — | — | EP | disclosed |
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | ENTASIS THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
| US-9040528-B2 | Chemical compounds 542 | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | ASTRAZENECA AB (SE) | 2014-05-08 | — | — | US | disclosed |
| US-8658641-B2 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2014-02-25 | — | — | US | disclosed |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | ALDH1A1 535/4885MEN1 488/4885GAA 408/4885 |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | SDHB, SDHA, RORC | ALDH1A1 664/4885MEN1 1594/4885GAA 805/4885 |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | ALDH1A1 535/4885MEN1 488/4885GAA 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.